About the Authors
- Andreas Stang
-
*To whom correspondence should be addressed. E-mail: andreas.stang@medizin.uni-halle.de (AS); E-mail: turnere@ohsu.edu (EHT)
- Hans-Werner Hense
- Karl-Heinz Jöckel
- Erick H Turner
-
*To whom correspondence should be addressed. E-mail: andreas.stang@medizin.uni-halle.de (AS); E-mail: turnere@ohsu.edu (EHT)
- Martin R Tramèr
Competing Interests
AS declares that he has no competing interests. HWH received lecture fees on several occasions from various pharmaceutical companies. His research activities are marginally funded (less than 5% of total) by industrial sponsors. KHJ is involved in many clinical and epidemiological projects, several of them sponsored by the pharmaceutical industry. EHT is on the speaker's bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. He has provided outside consulting to Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sepracor. He has also received funding for clinical drug trials, which can be spent only for research purposes and which has no effect on his income, from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, and DOV Pharmaceuticals. MRT has been a scientific consultant to Pfizer, Merck, Janssen-Cilag, and Sintetica. He has also received lecture fees from various pharmaceutical companies.